Synergy of Immunostimulatory Genetherapy with Immune Checkpoint Blockade Motivates Immune Response to Eliminate Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergy of Immunostimulatory Genetherapy with Immune Checkpoint Blockade Motivates Immune Response to Eliminate Cancer
Authors
Keywords
-
Journal
ADVANCED FUNCTIONAL MATERIALS
Volume -, Issue -, Pages 2100715
Publisher
Wiley
Online
2021-03-22
DOI
10.1002/adfm.202100715
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A review of cancer immunotherapy toxicity
- (2020) Lucy Boyce Kennedy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Time to dissect the autoimmune etiology of cancer antibody immunotherapy
- (2020) Michael Dougan et al. JOURNAL OF CLINICAL INVESTIGATION
- Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
- (2020) John D. Martin et al. Nature Reviews Clinical Oncology
- Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer
- (2020) Kuan-Wei Huang et al. Science Advances
- Immunotherapy, Inflammation and Colorectal Cancer
- (2020) Charles Robert Lichtenstern et al. Cells
- Acquired Resistance to Immune Checkpoint Inhibitors
- (2020) Adam J. Schoenfeld et al. CANCER CELL
- Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma
- (2020) Emilien Loeuillard et al. JOURNAL OF CLINICAL INVESTIGATION
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
- (2019) Hongwei Du et al. CANCER CELL
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- (2019) A B Schrock et al. ANNALS OF ONCOLOGY
- Macrophages and Metabolism in the Tumor Microenvironment
- (2019) Ilio Vitale et al. Cell Metabolism
- Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ
- (2019) Chang Liu et al. IMMUNITY
- Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
- (2019) Kloten et al. Cells
- Effects of interleukin-2 in immunostimulation and immunosuppression
- (2019) Jonathan G. Pol et al. JOURNAL OF EXPERIMENTAL MEDICINE
- An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy
- (2019) Lu Lu et al. BIOMATERIALS
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
- (2018) Krijn K. Dijkstra et al. CELL
- The great escape: how cationic polyplexes overcome the endosomal barrier
- (2018) Tanja Bus et al. Journal of Materials Chemistry B
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression
- (2017) Yu Zhu et al. IMMUNITY
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Emerging targets in cancer immunotherapy
- (2017) Samantha Burugu et al. SEMINARS IN CANCER BIOLOGY
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- Exploring the Role of RGD-Recognizing Integrins in Cancer
- (2017) Markus Nieberler et al. Cancers
- Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target
- (2016) Michael T. Werner et al. BLOOD
- Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
- (2016) Malte Mohme et al. Nature Reviews Clinical Oncology
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Integrin αvβ3 Drives Slug Activation and Stemness in the Pregnant and Neoplastic Mammary Gland
- (2014) Jay S. Desgrosellier et al. DEVELOPMENTAL CELL
- Non-viral vectors for gene-based therapy
- (2014) Hao Yin et al. NATURE REVIEWS GENETICS
- Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity
- (2013) Aleksandra M. Dudek et al. Frontiers in Immunology
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
- (2010) Subhra K Biswas et al. NATURE IMMUNOLOGY
- An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progression
- (2009) Jay S Desgrosellier et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now